Navigation Links
Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:10/14/2010

tate or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  Anadys believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is developing ANA598, a direct-acting antiviral or DAA, for the treatment of hepatitis C. In an ongoing Phase II study, Anadys has completed 12 weeks of dosing ANA598 added to current standard of care. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' expectations regarding its proposed public offering, Anadys' expected use of proceeds from the offering, Anadys' development programs including the anticipated timing for commencement of its Phase IIb study of ANA598, and Anadys' ability to develop novel medicines in the area of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, there are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. In addition, the results of preclinical and early clinical studies
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/11/2014)... 11, 2014 Neurelis, Inc. ("Neurelis") today announced ... the option held by Biotie to purchase Neurelis, clearing ... NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients ... past year, Biotie has advanced the development program for ... pivotal clinical work required for NDA submission to the ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... published in an upcoming issue of,Anti-Cancer Drugs , ... today announced that two peer-reviewed publications,will feature Protox's ... ("JNCI") has published the work conducted by Dr. ... in collaboration,with Protox scientists. The paper describes the ...
... 20, 2007--Researchers studying influenza,transmission patterns in the ... uncovered the unexpected finding that,each season influenza ... to the more populated centers. Their work, ... of the National Institutes,of Health (NIH), can ...
Cached Medicine Technology:Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 2Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 3Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3
(Date:7/13/2014)... (PRWEB) July 14, 2014 Worldwide ladies ... selection. Angeldress.co.uk has taken a different approach and ... fresh items are offered in more colour choices that ... a famous brand of women’s special occasion apparels. The ... Its dress specialists are working hard to create the ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Ticket Down ... Real Madrid Tickets . For the fifth straight year ... Cup will be held at American stadiums this summer. The ... on American soil. The eight teams are split into two ... stage, the top two teams will compete to become champion. ...
(Date:7/13/2014)... inexpensive, portable, microchip-based test for diagnosing type-1 diabetes ... better understand the disease, according to the device,s ... , Described in a paper to be published ... the test employs nanotechnology to detect type-1 diabetes ... the two main forms of diabetes mellitus, which ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The North American ... million in 2013 to $5,450 million by 2018, at a ... systems market is expanding at a rapid pace in North ... ever tightening laws on water & wastewater storage and collection, ... infrastructure. The market is expanding at a healthy rate in ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... more respectful, SAN DIEGO, March 19 Over one-third ... to three years, find a non-nursing,job, work part-time, or work ... AMN Healthcare, the largest health care staffing firm in,the country, ... baby,boomer nurses may be facing career burn-out. About 46 percent ...
... fast and precise ... ALTO, Calif., March 19 Varian Medical,Systems (NYSE: ... centers in North,America and Europe to further the development ... fast and precise,cancer treatments. RapidArc makes it possible to ...
... Names New President and CEO, MIAMI, March 19 ... (NPF) announced today that Joyce A.,Oberdorf has been named ... was most recently Vice President, Policy, Planning,and Communications at ... "Ms. Oberdorf is an outstanding choice to help NPF ...
... Johnson & Johnson Vision ... Contact Lenses, JACKSONVILLE, Fla., March 19 Johnson ... the ACUVUE(R) The Difference is,Real(TM) Trip to Beijing Sweepstakes, ... performance. The sweepstakes runs March 18,through April 11, 2008, ...
... China, March 19 /Xinhua-PRNewswire-FirstCall/ -- China,Nepstar Chain Drugstore Ltd. ... largest drugstore chain in China based on the number ... the,quarter and fiscal year ended December 31, 2007., ... December 31, 2007: -- Revenues increased 9.5% to ...
... Mustang at the New York, International Auto Show to raise money for breast ... ... Komen Race for the Cure - to $500 for ... more than $95 million in, cash and in-kind contributions for breast cancer education and ...
Cached Medicine News:Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 3Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 4Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 5Health News:National Parkinson Foundation Announces Its New President and CEO 2Health News:National Parkinson Foundation Announces Its New President and CEO 3Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 2Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 2Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 4Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 5Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 6Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 7Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 8Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 9Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 10Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 11Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 12Health News:Ford Launches 'Warriors in Pink' Mustang for '09, Doubles Contributions To Race For The Cure 2
Zero clearance, front breathing, undercounter refrigeration system....
Designed to meet the requirements of reagent grade water for routine analysis....
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: